NCT06007638

A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants

A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3876602 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The aim of this study is to evaluate the safety, tolerability and PK of LY3876602 after administering it as single ascending doses and, following a data review, proceeding to multiple ascending doses in healthy participants. Blood tests will also be performed to check how much LY3876602 gets into the bloodstream and cerebrospinal fluid (CSF) and how long it takes the body to eliminate it. Following the screening visit for Part A, the study will last up to approximately 20 weeks., and a subgroup of participants will consent to CSF collections The study will last up to approximately 28 weeks for Part B. All participants will consent to CSF collections.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3876602	Administered IV.
DRUG	Placebo	Administered IV.

Timeline

• Start date: 2023-08-23
• Primary completion: 2025-09-20
• Completion: 2025-09-20
• First posted: 2023-08-23
• Last updated: 2025-09-24

Locations

1 site across 1 country: Netherlands